---
title: "05:35 ETLeading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market"
description: "Insight Lifetech, a leading Chinese innovative medical device manufacturer, has successfully listed on the Shanghai Stock Exchange's STAR Market. The company issued shares at CNY17.52, opening at CNY5"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274956073.md"
published_at: "2026-02-05T10:37:17.000Z"
---

# 05:35 ETLeading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

> Insight Lifetech, a leading Chinese innovative medical device manufacturer, has successfully listed on the Shanghai Stock Exchange's STAR Market. The company issued shares at CNY17.52, opening at CNY50.31, with a market cap of CNY20.98 billion. Founded in 2015, Insight Lifetech focuses on precision cardiovascular solutions and has developed key products like the IVUS and FFR systems. The IPO marks a significant milestone for domestic medical device innovation in China, showcasing the country's growing competitiveness in the medtech sector.

, /PRNewswire/ -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion.

Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company's development in the D round. Before the company's IPO, Qiming Venture Partners held a more than 6% stake in Insight Lifetech and was one of its major institutional investors.

Founded in 2015, Insight Lifetech is dedicated tondeveloping innovative solutions with the potential to transform precision diagnosis and treatment of cardiovascular diseases. The company is the only domestic medical device company in China with a product portfolio in both precision intravascular physiology and imaging, including the first and only domestic fractional flow reserve (FFR) system approved by NMPA in China, and intravascular ultrasound (IVUS) system, which was the first domestic IVUS system to have entered clinical trialsand completed patient enrollment.

Since its establishment, Insight Lifetech has continuously invested in the fields of coronary artery diseases, peripheral vascular diseases, and atrial fibrillation based on the clinical needs of cardiovascular disease diagnosis and the development of cutting-edge technologies. It has now brought 11 products into the market and has more products under development in diverse categories, including IVUS system, FFR system, vascular access products, and electrophysiological solutions, etc.

The company's core product, the IVUS system, is the first independently-developed 60MHz high-definition high-speed IVUS product approved in China and the first China-made product approved by CE MDR. The product gained the largest market share in China and reduced the country's dependence on imported products immediately after coming into the market. The FFR system, another core product of the company, is China's first approved domestically-made product in FFR field and the first China-made product approved to to overseas (by CE MDR). The two products are expected to help enhance the clinical practice of precision-guided percutaneous coronary intervention (PCI) surgeries.

Song Liang, Founder, Chairman & CEO of Insight Lifetech stated，"Since establishment, Insight Lifetech has consistently adhered to the mission 'To transform healthcare through innovation and quality', dedicating to innovating intelligence-powered precision cardiovascular intervention. With unwavering passion and relentless effort, we have filled a critical gap in China's medical device industry—a sector characterized by the highest technological barriers and the longest industrial chain: high-performance precision cardiovascular interventional devices.

Moving forward, we will continue to hold our position at the forefront of innovation in precision cardiovascular intervention, remain clinically focused, pursue uncompromising quality, and demonstrate the robust power of Chinese innovation to the world. "

"Insight Lifetech is deeply committed to transfer clinical insights and technological capabilities to innovative and differentiated ntherapies in the cardiovascular intervention field, for the benefits of patients and physicians, worldwide. The dedicated team convinced us that it can make continuous breakthroughs in the field of innovative medical devices. The successful IPO of Insight Lifetech is not only an important verification of the development path of domestic cardiovascular innovative medical devices, but also demonstrates the rapid rise of China's global competitiveness in medtech innovation. Qiming Venture Partners believes that China's clinical experience, engineering capabilities, and entrepreneurship as well as advantages in supply chains can cultivate a generation of innovative medical device products which are competitive worldwide. We hope to work with ambitious entrepreneurs, to develophigh-quality products, and to co-build great medical device companies from China," Oscar Zhang, a partner of Qiming Venture Partners, said.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

### Related Stocks

- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [159898.CN - China Merchants CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159898.CN.md)
- [688712.CN - Insight Lifetech](https://longbridge.com/en/quote/688712.CN.md)
- [562600.CN - ChinaAMC CSI All Share Health Care Devices ETF](https://longbridge.com/en/quote/562600.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [159883.CN - Maxwealth CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159883.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 UBT251 在华二期临床数据亮眼，减重效果近 20% | 诺和诺德授权药 UBT251 中国二期临床数据亮眼：用药 24 周体重最高减 19.7%（安慰剂仅 2%），公司称 “非常受鼓舞”。但受 Cagrisema 负面消息拖累，股价仍跌超 4%。诺和诺德已支付 2 亿美元首付款，总交易或达 20 | [Link](https://longbridge.com/en/news/276728466.md) |
| 埃隆·马斯克的 Neuralink 在中国激发了脑机接口技术的竞赛 | Neuralink，由埃隆·马斯克创立，正在推动中国脑机接口（BCI）发展的热潮，像 NeuroXess 这样的初创公司迅速进入人体试验阶段。NeuroXess 于 2021 年成立，已经在患者身上测试植入物。中国政府已将 BCI 列为战略 | [Link](https://longbridge.com/en/news/276460367.md) |
| 中国抗体-B 获得中国 IND 批准，将 SM17 用于治疗炎症性肠病 | 中国抗体-B（SinoMab Bioscience Ltd.）已获得中国国家药品监督管理局批准，进行针对 SM17 在炎症性肠病中的研究新药申请，扩展其在特应性皮炎以外的应用。该公司已完成 I 期研究，并计划推进至 II 期临床试验。SM1 | [Link](https://longbridge.com/en/news/276765156.md) |
| 上海复星医药旗下子公司在中国获得肺癌药物的试验许可 | 上海复星医药子公司获得中国肺癌药物临床试验批准 | [Link](https://longbridge.com/en/news/276886600.md) |
| 和铂医药（SEHK:2142）在与 Solstice Oncology 达成合作后，关于 HBM4003 在大中华区以外的权益的估值 | HBM Holdings（香港证券交易所代码：2142）已与 Solstice Oncology 达成独家合作，负责其临床资产 HBM4003 在大中华区以外的市场。该公司的股票在一天内上涨了 4.41%，过去一周上涨了 8.12%，过去一 | [Link](https://longbridge.com/en/news/276700073.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.